A combined Phase I/II safety and feasibility trial of MDG1011, in patients with advanced hematological diseases: acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma

Trial Profile

A combined Phase I/II safety and feasibility trial of MDG1011, in patients with advanced hematological diseases: acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma

Planning
Phase of Trial: Phase I/II

Latest Information Update: 28 Aug 2017

At a glance

  • Drugs MDG 1011 (Primary)
  • Indications Acute myeloid leukaemia; Multiple myeloma; Myelodysplastic syndromes
  • Focus Adverse reactions; First in man
  • Sponsors MediGene AG
  • Most Recent Events

    • 28 Aug 2017 According to a MediGene AG media release, this trial is intended to be initiated by the end of 2017.
    • 10 Jul 2017 According to a MediGene AG media release, clinical trial authorization application (CTA) has submitted to the German authority Paul-Ehrlich-Institute (PEI).The final study design will be made available after CTA approval by PEI.
    • 27 Mar 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top